Research Analysts Set Expectations for FOLD Q2 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Amicus Therapeutics in a research report issued to clients and investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz forecasts that the biopharmaceutical company will earn ($0.01) per share for the quarter. The consensus estimate for Amicus Therapeutics' current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics' Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.04 EPS.

Several other research analysts have also commented on the stock. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Bank of America increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, October 17th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $16.88.

Amicus Therapeutics Trading Up 1.1 %

Shares of FOLD traded up $0.10 during mid-day trading on Tuesday, hitting $9.51. 1,774,523 shares of the company's stock traded hands, compared to its average volume of 2,434,944. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $2.84 billion, a P/E ratio of -27.97, a PEG ratio of 1.43 and a beta of 0.62. The business's 50-day moving average price is $9.68 and its 200-day moving average price is $10.53. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.03.

Institutional Trading of Amicus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics during the third quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. raised its stake in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 1,569 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new position in shares of Amicus Therapeutics in the 3rd quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics during the third quarter valued at $55,000.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 22,901 shares of company stock valued at $259,863 in the last 90 days. Corporate insiders own 2.20% of the company's stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.